

Real-World Treatment Outcomes in Black, Hispanic, Asian, and White People with Multiple Sclerosis Treated with Fumarates in the US

Sophia Woodson,¹ Edward J. Gettings,² Chu-Yueh Guo,³ Sylvia Klineova,⁴ Jong-Mi Lee,⁵ Rebecca S. Romero,⁶ Aljoeson Walker,⁷ Kinyee Fong,⁸ Jason P. Mendoza,⁸ Nicholas Belviso,⁸ Boyang Bian,⁸ James B. Lewin,⁸ Sai L. Shankar^{8, *}

¹University Hospitals, Cleveland, OH, USA

²Temple Health, Philadelphia, PA, USA

³University of California San Francisco Health, San Francisco, CA, USA

⁴Mount Sinai, New York, NY, USA

⁵Stanford Medicine, Palo Alto, CA, USA

⁶University of Texas Health, San Antonio, TX, USA

⁷Medical University of South Carolina, Charleston, SC, USA

⁸Biogen, Cambridge, MA, USA

***Corresponding author:**

Sai L. Shankar, PhD, FAAN

Full Postal address: Biogen, 225 Binney St, Cambridge, MA 02143 USA


Tel +1 781 464 4674

sai.shankar@biogen.com


Supplementary Material

Figure S1A HRU rates and **B** HCC.

A



B



Error bars represent the 95% CI

CI confidence interval, HRU healthcare resource use, HCC healthcare cost